Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SUTRO BIOPHARMA, INC.

(STRO)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
7.420 USD   -3.64%
11/23Sutro Biopharma to Participate in Upcoming Investor Conferences
AQ
11/09Transcript : Sutro Biopharma, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-09-2022 08:35 AM
CI
11/09HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates

06/27/2022 | 07:30pm EST

Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates (iADCs). The collaboration leverages the unique cancer-fighting potential of iADCs as a novel modality, enabled by Sutro's ability to engineer complex conjugated antibodies, and Astellas' global oncology R&D expertise. This strategic partnership will engage in the development of iADCs, a next generation modality with the potential for effective and efficient approaches for treatment of cold tumors so as to bring new drug therapies to patients who do not respond to existing therapies.

An iADC, which combines an antibody with a small molecule compound that induces immunogenic cell death in addition to an immune activating molecule, has the potential to boost the anti-cancer action. This partnership will enable Astellas and Sutro to mutually leverage strengths in their respective fields to accelerate iADC development for three distinct biological targets; Sutro will engage in research and preclinical studies to identify candidate compounds and then Astellas will pursue clinical development. Sutro has advanced technologies for linking drugs to antibodies and proprietary component parts, including candidate antibodies and linkable cytotoxins and immunostimulatory molecules.

For development of iADCs, Astellas will utilize the strength of its global R&D and commercialization capabilities in the area of antibodies and the small molecular components. These iADCs may have the potential to provide new therapeutic options for treatment of cancers for which no broadly effective therapy is currently available. Under the terms of the agreement, Sutro will receive an upfront cash payment of USD 90 million to develop iADCs for three biological targets and may be eligible to receive up to USD 422.5 million in development, regulatory and commercial milestones for each product candidate, and tiered royalties ranging from low double-digit to mid-teens on worldwide sales of any commercial products that may result from the collaboration, subject to Sutro's cost and profit sharing option for the United States.

Sutro has the option to share in the costs and profits for developing and commercializing product candidates in the United States. If Sutro exercise this option for a particular product candidate, Astellas and Sutro will equally share the costs of such co-development and co-commercialization, with the resulting profits/losses from co-commercialization also shared equally in the United States.


ę S&P Capital IQ 2022
All news about SUTRO BIOPHARMA, INC.
11/23Sutro Biopharma to Participate in Upcoming Investor Conferences
AQ
11/09Transcript : Sutro Biopharma, Inc. Presents at Credit Suisse 31st Annual Heal..
CI
11/09HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating
MT
11/08Earnings Flash (STRO) SUTRO BIOPHARMA Reports Q3 Revenue $25.1M
MT
11/08SUTRO BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
11/08Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/08Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and S..
AQ
11/03Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology ..
AQ
11/02Sutro Biopharma to Participate in Upcoming Investor Conferences
AQ
10/24Sutro Biopharma, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on SUTRO BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 65,0 M - -
Net income 2022 -127 M - -
Net cash 2022 166 M - -
P/E ratio 2022 -2,89x
Yield 2022 -
Capitalization 426 M 426 M -
EV / Sales 2022 4,01x
EV / Sales 2023 6,88x
Nbr of Employees 259
Free-Float 94,3%
Chart SUTRO BIOPHARMA, INC.
Duration : Period :
Sutro Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUTRO BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 7,42 $
Average target price 21,38 $
Spread / Average Target 188%
EPS Revisions
Managers and Directors
William J. Newell President, Chief Executive Officer & Director
Edward C. Albini Chief Financial Officer & Secretary
Connie L. Matsui Chairman
Henry Heinsohn Vice President-Technology & Innovation
Trevor Hallam Chief Scientific Officer & President-Research
Sector and Competitors
1st jan.Capi. (M$)
SUTRO BIOPHARMA, INC.-50.13%426
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930